Similar articles for PMID: 28296619

Year	Number of Results
2009	1
2012	4
2013	2
2014	7
2015	16
2016	25
2017	27
2018	18
2019	15
2020	12
2021	8
2022	4
2023	3
2024	0

1

Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar.

Kim S, Song J, Park S, Ham S, Paek K, Kang M, Chae Y, Seo H, Kim HC, Flores M. Kim S, et al. MAbs. 2017 May/Jun;9(4):704-714. doi: 10.1080/19420862.2017.1305530. Epub 2017 Mar 15. MAbs. 2017. PMID: 28296619 Free PMC article.

2

Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin^® with a Panel of Sensitive and Orthogonal Methods Including a Novel FcγRIIIa Affinity Chromatography Technology.

Xie L, Zhang E, Xu Y, Gao W, Wang L, Xie MH, Qin P, Lu L, Li S, Shen P, Jiang W, Liu S. Xie L, et al. BioDrugs. 2020 Jun;34(3):363-379. doi: 10.1007/s40259-020-00407-0. BioDrugs. 2020. PMID: 32072477 Free PMC article.

3

Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.

Lee J, Kang HA, Bae JS, Kim KD, Lee KH, Lim KJ, Choo MJ, Chang SJ. Lee J, et al. MAbs. 2018 May/Jun;10(4):547-571. doi: 10.1080/19420862.2018.1440170. Epub 2018 Mar 14. MAbs. 2018. PMID: 29482416 Free PMC article.

4

Drifts in N-Linked Glycosylation Result in ADCC Potency Variation of Perjeta® from August 2020 to October 2021 in China.

Yao B, Zhang D, Cao W, Yang G, Li W, Hui X, Ouyang P, Chen G, Liu B. Yao B, et al. Biomed Res Int. 2022 Apr 30;2022:7868391. doi: 10.1155/2022/7868391. eCollection 2022. Biomed Res Int. 2022. PMID: 35535043 Free PMC article.

5

Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment.

Lee JH, Paek K, Moon JH, Ham S, Song J, Kim S. Lee JH, et al. BioDrugs. 2019 Aug;33(4):411-422. doi: 10.1007/s40259-019-00362-5. BioDrugs. 2019. PMID: 31190280 Free PMC article.

6

Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study.

Joshi S, Rathore AS. Joshi S, et al. BioDrugs. 2020 Apr;34(2):209-223. doi: 10.1007/s40259-020-00404-3. BioDrugs. 2020. PMID: 31975160

7

In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.

Chen L, Wang L, Shion H, Yu C, Yu YQ, Zhu L, Li M, Chen W, Gao K. Chen L, et al. MAbs. 2016 Oct;8(7):1210-1223. doi: 10.1080/19420862.2016.1204502. Epub 2016 Jul 5. MAbs. 2016. PMID: 27380163 Free PMC article.

8

Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab).

Hong J, Lee Y, Lee C, Eo S, Kim S, Lee N, Park J, Park S, Seo D, Jeong M, Lee Y, Yeon S, Bou-Assaf G, Sosic Z, Zhang W, Jaquez O. Hong J, et al. MAbs. 2017 Feb/Mar;9(2):364-382. doi: 10.1080/19420862.2016.1264550. Epub 2016 Dec 22. MAbs. 2017. PMID: 28005456 Free PMC article.

9

Physicochemical and biological characterization of a biosimilar trastuzumab.

López-Morales CA, Miranda-Hernández MP, Juárez-Bayardo LC, Ramírez-Ibáñez ND, Romero-Díaz AJ, Piña-Lara N, Campos-García VR, Pérez NO, Flores-Ortiz LF, Medina-Rivero E. López-Morales CA, et al. Biomed Res Int. 2015;2015:427235. doi: 10.1155/2015/427235. Epub 2015 May 17. Biomed Res Int. 2015. PMID: 26075238 Free PMC article.

10

Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.

Cuello HA, Segatori VI, Alberto M, Pesce A, Alonso DF, Gabri MR. Cuello HA, et al. BioDrugs. 2016 Jun;30(3):225-31. doi: 10.1007/s40259-016-0171-8. BioDrugs. 2016. PMID: 27053342

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

122 results

Results by year